Spark Therapeutics (ONCE) Stock Rating Reaffirmed by Credit Suisse Group

Credit Suisse Group reissued their hold rating on shares of Spark Therapeutics (NASDAQ:ONCE) in a research report sent to investors on Monday. Credit Suisse Group currently has a $44.00 price target on the biotechnology company’s stock.

A number of other equities analysts have also recently commented on ONCE. Cantor Fitzgerald set a $103.00 target price on Spark Therapeutics and gave the company a buy rating in a report on Friday, September 21st. William Blair reiterated a buy rating on shares of Spark Therapeutics in a research note on Friday, September 21st. Raymond James reiterated a buy rating on shares of Spark Therapeutics in a research note on Friday, September 21st. ValuEngine cut Spark Therapeutics from a hold rating to a sell rating in a research note on Thursday, October 4th. Finally, Guggenheim started coverage on Spark Therapeutics in a research note on Tuesday, October 9th. They issued a buy rating and a $70.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and twelve have issued a buy rating to the company’s stock. The company presently has an average rating of Buy and an average target price of $65.20.

Spark Therapeutics stock traded down $0.10 during midday trading on Monday, reaching $43.50. 6,552 shares of the stock traded hands, compared to its average volume of 555,550. Spark Therapeutics has a 12-month low of $34.53 and a 12-month high of $96.59. The stock has a market capitalization of $1.67 billion, a price-to-earnings ratio of -5.70 and a beta of 1.98. The company has a debt-to-equity ratio of 0.09, a current ratio of 10.71 and a quick ratio of 10.36.



Spark Therapeutics (NASDAQ:ONCE) last announced its earnings results on Tuesday, November 6th. The biotechnology company reported ($1.26) EPS for the quarter, missing analysts’ consensus estimates of ($1.04) by ($0.22). Spark Therapeutics had a negative net margin of 127.82% and a negative return on equity of 14.18%. The firm had revenue of $10.70 million for the quarter, compared to analysts’ expectations of $27.44 million. During the same quarter last year, the business earned ($1.90) earnings per share. The business’s revenue was up 463.2% compared to the same quarter last year. Equities research analysts anticipate that Spark Therapeutics will post -1.53 earnings per share for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Teachers Advisors LLC raised its position in shares of Spark Therapeutics by 1.4% during the 3rd quarter. Teachers Advisors LLC now owns 66,153 shares of the biotechnology company’s stock worth $3,609,000 after acquiring an additional 917 shares in the last quarter. Tocqueville Asset Management L.P. raised its position in shares of Spark Therapeutics by 2.7% during the 2nd quarter. Tocqueville Asset Management L.P. now owns 41,225 shares of the biotechnology company’s stock worth $3,412,000 after acquiring an additional 1,075 shares in the last quarter. Smith Asset Management Group LP raised its position in shares of Spark Therapeutics by 39.6% during the 3rd quarter. Smith Asset Management Group LP now owns 3,950 shares of the biotechnology company’s stock worth $215,000 after acquiring an additional 1,120 shares in the last quarter. Capital Fund Management S.A. raised its position in shares of Spark Therapeutics by 8.1% during the 2nd quarter. Capital Fund Management S.A. now owns 15,379 shares of the biotechnology company’s stock worth $1,273,000 after acquiring an additional 1,152 shares in the last quarter. Finally, Metropolitan Life Insurance Co. NY raised its position in shares of Spark Therapeutics by 13.1% during the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 10,207 shares of the biotechnology company’s stock worth $845,000 after acquiring an additional 1,180 shares in the last quarter.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.

Featured Story: Diversification For Individual Investors

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply